1
|
Reesink DJ, van de Garde EM, Somford DM, Meijer RP, Los M, Biesma DH, Horenblas S, van Melick HH, van der Nat PB. Development of the First Patient-centred Set of Outcomes for Muscle-invasive and Metastatic Bladder Cancer: A Multicentre Initiative. EUR UROL SUPPL 2021; 26:18-26. [PMID: 34337504 PMCID: PMC8317903 DOI: 10.1016/j.euros.2021.01.014] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/28/2021] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND To improve and compare outcomes in healthcare, it is necessary to standardise outcome measurements. There are no widely accepted standardised outcome measures reflecting quality of care for bladder cancer (BCa) patients. OBJECTIVE The aim of this study was to create a standardised set of outcomes for patients with muscle-invasive or metastatic BCa, using the value-based healthcare principles. DESIGN SETTING AND PARTICIPANTS A multidisciplinary working group of 25 healthcare professionals and patient representatives was assembled, to develop the set. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS We used an online RAND-modified Delphi process to prioritise, discuss, and reach consensus regarding the outcomes, case-mix variables, and treatment factors. RESULTS AND LIMITATIONS Recognising the heterogeneity of patients with BCa, the working group defined the scope as patients with muscle-invasive and metastatic BCa. A total of 24 outcomes, including ten patient-reported outcomes, were included in the standard set of outcomes, covering survival, complication rates, recurrence of disease, readmissions after treatment, and quality of life (QoL). Fourteen case-mix variables were included. The EQ-5D and European Organisation for Research and Treatment of Cancer quality of life (EORTC-QLQ) questionnaires were recommended to measure QoL. CONCLUSIONS We developed the first standardised set of patient-centred outcomes for muscle-invasive and metastatic BCa. The sue of this set enables institutions to monitor, compare, and improve the quality of BCa care, on an international level. PATIENT SUMMARY Our group of healthcare professionals and patient representatives recommended a standardised set of patient-centred outcomes to be followed during the treatment of patients with muscle-invasive or metastatic bladder cancer, in order to monitor, compare, and improve the quality of care.
Collapse
Affiliation(s)
- Daan J. Reesink
- Urology Department, St. Antonius Hospital, Utrecht/Nieuwegein, The Netherlands
| | | | - Diederik M. Somford
- Urology Department, Canisius Wilhelmina Hospital [CWZ], Nijmegen, The Netherlands
| | - Richard P. Meijer
- Urology Department, University Medical Center Utrecht (UMCU), Utrecht, The Netherlands
| | - Maartje Los
- Oncology Department, St. Antonius Hospital, Utrecht/Nieuwegein, The Netherlands
| | - Douwe H. Biesma
- Value Based Healthcare Department, St. Antonius Hospital, Utrecht/Nieuwegein, The Netherlands
| | - Simon Horenblas
- Urology Department, The Netherlands Cancer Institute – Antoni van Leeuwenhoek [NCI-AVL] Hospital, Amsterdam, The Netherlands
| | | | - Paul B. van der Nat
- Value Based Healthcare Department, St. Antonius Hospital, Utrecht/Nieuwegein, The Netherlands
- Scientific Center for Quality of Healthcare (IQ Healthcare), Radboud UMC, Nijmegen, The Netherlands
| | | |
Collapse
|
2
|
Tinti S, De Maria B, Parati M, Terzoni S, Rossi MC, Da Col D, Pairona G, Longhi C, Giudici E, Pidone I, Alberti A, Sofia M, Ramponi I, Urbano N, Tanaka K, Destrebecq A. Italian Version of Cancer Dyspnea Scale: Cultural-Linguistic and Clinical Validation in Patients With Advanced Cancer Disease in Palliative Care Settings. J Pain Symptom Manage 2021; 61:571-578.e1. [PMID: 33059018 DOI: 10.1016/j.jpainsymman.2020.10.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Revised: 10/06/2020] [Accepted: 10/08/2020] [Indexed: 10/23/2022]
Abstract
CONTEXT The Cancer Dyspnea Scale (CDS) is a self-reported multidimensional tool used for the assessment of dyspnea, a subjective experience of breathing discomfort, in patients with cancer. The scale describes dyspnea using three distinct factors: physical, psychological, and discomfort at rest. OBJECTIVES To crossculturally validate the Italian version of CDS (CDS-IT) and examine its content validity, feasibility, internal consistency, and construct validity in patients with advanced cancer. METHODS A cross-sectional study was conducted. CDS-IT was forward-backward translated, and its content was validated among a group of experts. Cronbach's α coefficients were used to assess the internal consistency. Construct validity was examined in terms of structural validity through confirmatory factor analysis, and convergent validity was examined with Visual Analogue Scale Dyspnea through the Pearson's correlation coefficient (r). Cancer Quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 Palliative Care) and Italian Palliative Outcome Scale were also tested. RESULTS The CDS-IT was crossculturally validated and showed satisfactory content validity. A total of 101 patients (mean age = 76 [SD = 12]; 53% females) were recruited in palliative care settings. CDS-IT reported a good internal consistency in the total score and its factors (α = 0.74-0.83). The factor analysis corresponded acceptably but not completely with the original study. CDS-IT strongly correlated with Visual Analogue Scale Dyspnea (r = 0.68) and moderately with Italian Palliative Outcome Scale and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 Palliative Care (r = 0.33-0.36, respectively). CONCLUSION The study findings supported the crosscultural validity of the CDS-IT. Its feasibility, internal consistency, and construct validity are satisfactory for clinical practice. The CDS-IT is available to health care professionals as a useful tool to assess dyspnea in patients with cancer.
Collapse
Affiliation(s)
- Stefania Tinti
- Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
| | | | - Monica Parati
- IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy; Neuroengineering and Medical Robotics Laboratory, Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy
| | - Stefano Terzoni
- ASST- Santi Paolo e Carlo, University of Milan, Milan, Italy
| | - Maria Cristiana Rossi
- ASST-Rhodense, Palliative Care, Hospice and Pain Therapy Department, Garbagnate Milanese, Milan, Italy
| | - Daria Da Col
- ASST Grande Ospedale Metropolitano Niguarda, Palliative Care - Hospice, Milan, Italy
| | - Giulia Pairona
- ASST Grande Ospedale Metropolitano Niguarda, Palliative Care - Hospice, Milan, Italy
| | - Carla Longhi
- ASST-Lariana, Palliative Care - Hospice, Mariano Comense, Como, Italy
| | - Elisa Giudici
- ASST-Lariana, Palliative Care - Hospice, Mariano Comense, Como, Italy
| | - Irene Pidone
- ASST-Lariana, Palliative Care - Hospice, Mariano Comense, Como, Italy
| | - Annalisa Alberti
- ASST-Rhodense Bachelor School of Nursing, University of Milan, Rho, Milan, Italy
| | - Michele Sofia
- ASST-Rhodense, Palliative Care, Hospice and Pain Therapy Department, Garbagnate Milanese, Milan, Italy
| | - Ida Ramponi
- ASST-Rhodense, Garbagnate Milanese, Milan, Italy
| | - Nicla Urbano
- ASST-Rhodense, Garbagnate Milanese, Milan, Italy
| | - Keiko Tanaka
- Palliative Care Department Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
| | - Anne Destrebecq
- Department of Biomedical Sciences for Health, University of Milan, Milan, Italy
| |
Collapse
|
3
|
McCaffrey N, Asser T, Fazekas B, Muircroft W, Agar M, Clark K, Eckermann S, Lee J, Joshi R, Allcroft P, Sheehan C, Currow DC. Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide. BMC Cancer 2020; 20:1050. [PMID: 33129304 PMCID: PMC7603764 DOI: 10.1186/s12885-020-07549-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2019] [Accepted: 10/21/2020] [Indexed: 02/07/2023] Open
Abstract
Background This analysis aims to evaluate health-related quality of life (HrQoL) (primary outcome for this analysis), nausea and vomiting, and pain in patients with inoperable malignant bowel obstruction (IMBO) due to cancer or its treatments randomised to standardised therapies plus octreotide or placebo over a maximum of 72 h in a double-blind clinical trial. Methods Adults with IMBO and vomiting recruited through 12 services spanning inpatient, consultative and community settings in Australia were randomised to subcutaneous octreotide infusion or saline. HrQoL was measured at baseline and treatment cessation (EORTC QLQ-C15-PAL). Mean within-group paired differences between baseline and post-treatment scores were analysed using Wilcoxon Signed Rank test and between group differences estimated using linear mixed models, adjusted for baseline score, sex, age, time, and study arm. Results One hundred six of the 112 randomised participants were included in the analysis (n = 52 octreotide, n = 54 placebo); 6 participants were excluded due to major protocol violations. Mean baseline HrQoL scores were low (octreotide 22.1, 95% CI 14.3, 29.9; placebo 31.5, 95% CI 22.3, 40.7). There was no statistically significant within-group improvement in the mean HrQoL scores in the octreotide (p = 0.21) or placebo groups (p = 0.78), although both groups reported reductions in mean nausea and vomiting (octreotide p < 0.01; placebo p = 0.02) and pain scores (octreotide p < 0.01; placebo p = 0.03). Although no statistically significant difference in changes in HrQoL scores between octreotide and placebo were seen, an adequately powered study is required to fully assess any differences in HrQoL scores. Conclusion The HrQoL of patients with IMBO and vomiting is poor. Further research to formally evaluate the effects of standard therapies for IMBO is therefore warranted. Trial registration Australian New Zealand Clinical Trials Registry ACTRN12608000211369 (date registered 18/04/2008) Supplementary Information The online version contains supplementary material available at 10.1186/s12885-020-07549-y.
Collapse
Affiliation(s)
- Nikki McCaffrey
- Deakin Health Economics, Centre for Population Health Research, School of Health and Social Development, Deakin University, Geelong, Victoria, Australia. .,Palliative & Supportive Services, Flinders University, Bedford Park, South Australia, Australia.
| | - Tegan Asser
- School of Medicine, Flinders University, Bedford Park, South Australia, Australia
| | - Belinda Fazekas
- IMPACCT, Faculty of Health, University of Technology, Ultimo, New South Wales, Australia.,Australian National Cancer Symptom Trials Group, University of Technology Sydney, Ultimo, New South Wales, 2007, Australia
| | - Wendy Muircroft
- Southern Adelaide Palliative Services, Southern Adelaide Local Health Network, Bedford Park, South Australia, Australia
| | - Meera Agar
- IMPACCT, Faculty of Health, University of Technology, Ultimo, New South Wales, Australia.,Australian National Cancer Symptom Trials Group, University of Technology Sydney, Ultimo, New South Wales, 2007, Australia.,Liverpool Hospital, South West Sydney Local Health District, Liverpool, New South Wales, Australia
| | - Katherine Clark
- Cancer & Palliative Care Network, Northern Sydney Local Health District, St Leonards, New South Wales, Australia.,Northern Clinical School, The University of Sydney, St Leonards, New South Wales, Australia
| | - Simon Eckermann
- Centre for Health Service Development, Australian Health Services Research Institute, University of Wollongong, Wollongong, New South Wales, Australia
| | - Jessica Lee
- IMPACCT, Faculty of Health, University of Technology, Ultimo, New South Wales, Australia.,Concord Centre for Palliative Care, Concord Repatriation General Hospital, Concord, New South Wales, Australia
| | - Rohit Joshi
- Medical Oncology, Lyell McEwin Hospital, Adelaide, South Australia, Australia
| | - Peter Allcroft
- Southern Adelaide Palliative Services, Southern Adelaide Local Health Network, Bedford Park, South Australia, Australia
| | | | - David C Currow
- IMPACCT, Faculty of Health, University of Technology, Ultimo, New South Wales, Australia.,Australian National Cancer Symptom Trials Group, University of Technology Sydney, Ultimo, New South Wales, 2007, Australia.,Wolfson Palliative Care Research Centre, University of Hull, Hull, HU6 7RX, England
| |
Collapse
|
4
|
Bagcivan G, Bredle J, Bakitas M, Guciz Dogan B. Reliability and Validity of the Turkish Version of the FACIT-PAL Quality of Life Instrument. J Pain Symptom Manage 2019; 58:297-305.e4. [PMID: 31096004 DOI: 10.1016/j.jpainsymman.2019.04.020] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/07/2019] [Revised: 04/15/2019] [Accepted: 04/15/2019] [Indexed: 12/22/2022]
Abstract
CONTEXT The accurate measurement of quality of life (QoL) among people with chronic and incurable illnesses is essential for evaluating service delivery, understanding the impact of illness and treatment effects, and testing intervention effectiveness. Palliative care interventions are relatively new in Turkey; therefore, it is important that reliable and valid QoL instruments are available to evaluate palliative care effectiveness in Turkish speakers. OBJECTIVES The purpose of this study was to translate, linguistically validate, and determine the psychometric properties of the newly translated Functional Assessment of Chronic Illness Therapy-Palliative Care (FACIT-Pal) scale (FACIT-Pal-TR) for Turkish-speaking cancer patients. METHODS We used standard multilingual translation and validation methods for the initial translation of the FACIT-Pal-TR and then assessed the psychometric properties of reliability and validity of the translated scale. We used the Karnofsky Performance Scale and Edmonton Symptom Assessment Scale to assess concurrent and construct validity. RESULTS A convenience sample of 232 cancer patients participated in this study. The Cronbach's alpha coefficient of FACIT-Pal-TR was 0.932 (between 0.732 and 0.860 for subscales). There was a statistically significant relationship between test and retest scores (r = 0.877, P < 0.001). The factor loadings of FACIT-Pal-TR were between 0.205 and 0.815. FACIT-Pal-TR construct validity was acceptable with 45 items and five subscales. There were statistically significant relationships between FACIT-Pal-TR scores and Edmonton Symptom Assessment Scale (P < 0.001) and Karnofsky Performance Scale (r = 0.656; P < 0.001) scores. CONCLUSIONS The FACIT-Pal-TR demonstrates strong reliability and validity for evaluating palliative care-specific QoL in Turkish cancer patients.
Collapse
Affiliation(s)
| | | | - Marie Bakitas
- School of Nursing, Center for Palliative and Supportive Care, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Bahar Guciz Dogan
- School of Medicine-Public Health, Hacettepe University, Ankara, Turkey
| |
Collapse
|
5
|
Ahlam A, Hind M, Haddou Rahou B, Rachid R, Hassan E. Quality of life of Moroccan patients on the palliative phase of advanced cancer. BMC Res Notes 2019; 12:351. [PMID: 31227021 PMCID: PMC6588852 DOI: 10.1186/s13104-019-4390-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2019] [Accepted: 06/14/2019] [Indexed: 11/10/2022] Open
Abstract
Objective The aim of this study is to assess the quality of life of caregiver’s. The study was conducted at the RABAT National Institute of Oncology in MOROCCO. Results 120 patients on the palliative phase of advanced cancer were included. Severe fatigue was observed in 64.2% of patients with an average of 90.55 ± 14.7. There was a positive association between functional dimensions and overall quality of life and a negative association between symptoms and overall quality of life. Patients under 30 years had a lower quality of life. According to the multi-varied analysis, physical function, emotional functioning and fatigue were significant predictors of Health related quality of life/overall quality of life (p < 0.05). Electronic supplementary material The online version of this article (10.1186/s13104-019-4390-1) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Aitouma Ahlam
- Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco. .,Translational Oncology Research Team, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.
| | - Mrabti Hind
- Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco.,Translational Oncology Research Team, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco
| | - Bouchra Haddou Rahou
- Research Department, Higher Institute of Nursing Professions and Technical Health, Rabat, Morocco
| | - Razine Rachid
- Laboratory of Social Medicine and Public Health, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco
| | - Errihani Hassan
- Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco.,Translational Oncology Research Team, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco
| |
Collapse
|
6
|
King MT, Agar M, Currow DC, Hardy J, Fazekas B, McCaffrey N. Assessing quality of life in palliative care settings: head-to-head comparison of four patient-reported outcome measures (EORTC QLQ-C15-PAL, FACT-Pal, FACT-Pal-14, FACT-G7). Support Care Cancer 2019; 28:141-153. [DOI: 10.1007/s00520-019-04754-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2018] [Accepted: 03/18/2019] [Indexed: 01/22/2023]
|
7
|
To What Extent Does Radiotherapy Improve the Quality of Life of Patients With Bone Metastasis?: A Prospective, Single-Institutional Study. Am J Clin Oncol 2019; 41:163-166. [PMID: 26535991 DOI: 10.1097/coc.0000000000000249] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE/OBJECTIVES Radiation therapy (RT) is an effective method of palliating painful bone metastases and improves the quality of life (QoL) of these patients. The purpose of this trial is 2-fold: to quantify the impact of RT in the QoL of patients with bone metastasis and to compare the QoL results between the most used schemes of RT at our Centre. MATERIALS AND METHODS A consecutive sample of patients with bone metastasis treated with RT in the Complejo Hospitalario de Navarra, Spain, was addressed between January 2011 and November 2012. The QoL was measured with the Quality of Life Questionnaire-C15-Palliative questionnaire, a short version of the European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire-C30 for palliative care. Two assessments were proposed for each patient: one on the first day of the treatment and the other one a month after the end of the radiotherapy sessions. One hundred and sixteen patients completed the first questionnaire and 75 completed the second one (65%). RESULTS Significant differences appeared in 9 domains, with better QoL in the second assessment. Five areas (physical functioning, global, fatigue, nausea, dyspnea, and constipation) showed little change (between 5 and 9 points), 3 (emotional functioning, insomnia, and appetite loss) showed moderate change (10 to 20 points), and 1 (pain) showed a very positive change (>30 points).When we compare the QoL scores between the 2 most used schemes of RT (30 Gy/10 fractions vs. 20 Gy/4 to 5 fractions), there are no significant differences in any QoL areas (and in 2 areas P was near 0.05). CONCLUSIONS Palliative RT is a very active treatment for patients with bone metastasis regardless of age, location, primary tumor, or RT scheme. RT significantly improves the QoL, fundamentally by controlling pain and reducing analgesic use. Shorter schemes of RT produce at least-if not better-the same effect on QL than longer schemes (30 Gy).
Collapse
|
8
|
McCaffrey N, Flint T, Kaambwa B, Fazekas B, Rowett D, Currow DC, Hardy J, Agar MR, Quinn S, Eckermann S. Economic evaluation of the randomised, double-blind, placebo-controlled study of subcutaneous ketamine in the management of chronic cancer pain. Palliat Med 2019; 33:74-81. [PMID: 30269638 DOI: 10.1177/0269216318801754] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background: Treating chronic, uncontrolled, cancer pain with subcutaneous ketamine in patients unresponsive to opioids and co-analgesics remains controversial, especially in light of recent evidence demonstrating ketamine does not have net clinical benefit in this setting. Aim: To evaluate the cost-effectiveness of subcutaneous ketamine versus placebo in this patient population. Design and setting: A within-trial cost-effectiveness analysis of the Australian Palliative Care Clinical Studies Collaborative’s randomised, double-blind, placebo-controlled trial of ketamine was conducted from a healthcare provider perspective. Mean costs and outcomes were estimated from participant-level data over 5 days including positive response, health-related quality of life (HrQOL) measured with the Functional Assessment of Chronic Illness Therapy–Palliative Care (FACIT-Pal), ketamine costs, medication usage and in-patient stays. Results: There was no statistically significant difference in responder rates, but higher toxicity and worse HrQOL for ketamine participants (mean change −3.10 (standard error (SE) 1.76), ketamine n = 93; 4.53 (SE 1.38), placebo n = 92). Estimated total mean costs were AU$706 higher per ketamine participant (AU$6608) compared with placebo (AU$5902), attributable to the cost of higher in-patient costs as well as costs of ketamine administration. The results were robust to sensitivity analyses accounting for different medication use costing methods and removal of cost outliers. Conclusion: The findings suggest subcutaneous ketamine in conjunction with opioids and standard adjuvant therapy is neither an effective nor cost-effective treatment for refractory pain in advanced cancer patients.
Collapse
Affiliation(s)
- Nikki McCaffrey
- 1 Deakin Health Economics, Centre for Population Health Research and School of Health and Social Development, Deakin University, Burwood, VIC, Australia.,2 Palliative and Supportive Services, Flinders University, Adelaide, SA, Australia
| | | | | | - Belinda Fazekas
- 2 Palliative and Supportive Services, Flinders University, Adelaide, SA, Australia
| | - Debra Rowett
- 5 Repatriation General Hospital, Daw Park and School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia
| | - David C Currow
- 2 Palliative and Supportive Services, Flinders University, Adelaide, SA, Australia.,6 Faculty of Health, University of Technology Sydney, Ultimo, NSW, Australia
| | - Janet Hardy
- 7 Department of Palliative and Supportive Care, Mater Health Services, Mater Research, University of Queensland, Brisbane, QLD, Australia
| | - Meera R Agar
- 8 Liverpool Hospital, South West Sydney Local Health District and University of Technology Sydney, Ultimo, NSW, Australia
| | - Steve Quinn
- 9 Swinburne University of Technology, Melbourne, VIC, Australia
| | - Simon Eckermann
- 10 Australian Health Services Research Institute, University of Wollongong, Wollongong, NSW, Australia
| |
Collapse
|
9
|
Taarnhøj GA, Kennedy FR, Absolom KL, Bæksted C, Vogelius IR, Johansen C, Velikova G, Pappot H. Comparison of EORTC QLQ-C30 and PRO-CTCAE™ Questionnaires on Six Symptom Items. J Pain Symptom Manage 2018; 56:421-429. [PMID: 29807157 DOI: 10.1016/j.jpainsymman.2018.05.017] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Revised: 05/15/2018] [Accepted: 05/16/2018] [Indexed: 12/22/2022]
Abstract
CONTEXT Clinical studies have over the past decade paid increasing attention to health-related quality of life data. Multiple questionnaires are often administered resulting in overlapping questions increasing patient burden. OBJECTIVES To examine the correlations between the commonly used European Organization for Research and Treatment of Cancer Quality of Life Questionnnaire-C30 (QLQ-C30) and the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™) on six coinciding items to determine consistency between overlapping items. METHODS Data were prospectively collected from patients attending two cancer centers in the U.K. Participants completed the QLQ-C30 version 3.0 every four weeks and the PRO-CTCAE at least once a week for 12 weeks. Data were collected via the Internet or an interactive voice response. For the six coinciding items in QLQ-C30 and PRO-CTCAE: pain, nausea, vomiting, constipation, diarrhea, and fatigue, comparisons were made between all possible related responses by aligning the four responses in the QLQ-C30 with two condensed versions of the five responses in the PRO-CTCAE. Consistency and reliability was determined with the intraclass correlation coefficient (ICC) and Cronbach's α. RESULTS About 247 patients completed 785 QLQ-C30 and 2501 PRO-CTCAE questionnaires. Moderate (ICC >0.5) to good (ICC >0.75) reliability and Cronbach's α >0.7 were found on all coinciding questions except for questions concerning the severity of nausea and vomiting as a result of relatively few patients responding to these questions. Items on frequency showed better correlations than the severity and interference items. CONCLUSION The good reliability and consistency between the QLQ-C30 and PRO-CTCAE support future attempts to minimize patient burden by shortening health-related quality of life questionnaires.
Collapse
Affiliation(s)
| | - Fiona R Kennedy
- Leeds Institute of Cancer and Pathology, School of Medicine, University of Leeds, Leeds, United Kingdom
| | - Kate L Absolom
- Leeds Institute of Cancer and Pathology, School of Medicine, University of Leeds, Leeds, United Kingdom
| | | | | | | | - Galina Velikova
- Leeds Institute of Cancer and Pathology, School of Medicine, University of Leeds, Leeds, United Kingdom
| | - Helle Pappot
- Department of Oncology, Rigshospitalet, Copenhagen, Denmark
| |
Collapse
|
10
|
Harding D, Giles SL, Brown MRD, Ter Haar GR, van den Bosch M, Bartels LW, Kim YS, Deppe M, deSouza NM. Evaluation of Quality of Life Outcomes Following Palliative Treatment of Bone Metastases with Magnetic Resonance-guided High Intensity Focused Ultrasound: An International Multicentre Study. Clin Oncol (R Coll Radiol) 2018; 30:233-242. [PMID: 29317145 PMCID: PMC5842401 DOI: 10.1016/j.clon.2017.12.023] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2017] [Revised: 11/27/2017] [Accepted: 11/29/2017] [Indexed: 11/26/2022]
Abstract
AIMS To determine quality of life (QoL) outcomes after palliation of pain from bone metastases using magnetic resonance-guided high intensity focused ultrasound (MR-guided HIFU), measured using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C15-PAL and the QLQ-BM22 questionnaires. MATERIALS AND METHODS Twenty patients undergoing MR-guided HIFU in an international multicentre trial self-completed the QLQ-C15-PAL and QLQ-BM22 questionnaires before and on days 7, 14, 30, 60 and 90 post-treatment. Descriptive statistics were used to represent changes in symptom and functional scales over time and to determine their clinical significance. QoL changes were compared in pain responders and non-responders (who were classified according to change in worst pain score and analgesic intake, between baseline and day 30). RESULTS Eighteen patients had analysable QoL data. Clinically significant improvements were seen in the QoL scales of physical functioning, fatigue, appetite loss, nausea and vomiting, constipation and pain in the 53% of patients who were classified as responders at day 30. No significant changes were seen in the 47% of patients who were non-responders at this time point. CONCLUSION Local treatment of pain from bone metastases with MR-guided HIFU, even in the presence of disseminated malignancy, has a substantial positive effect on physical functioning, and improves other symptomatic QoL measures. This indicated a greater response to treatment over and above pain control alone. MR-guided HIFU is non-invasive and should be considered for patients with localised metastatic bone pain and poor QoL.
Collapse
Affiliation(s)
- D Harding
- The CRUK Cancer Imaging Centre, The Institute of Cancer Research and Royal Marsden Hospital, MRI Unit, Sutton, Surrey, UK
| | - S L Giles
- The CRUK Cancer Imaging Centre, The Institute of Cancer Research and Royal Marsden Hospital, MRI Unit, Sutton, Surrey, UK.
| | - M R D Brown
- Pain Medicine Department, The Royal Marsden Hospital, Sutton, Surrey, UK
| | - G R Ter Haar
- The CRUK Cancer Imaging Centre, The Institute of Cancer Research and Royal Marsden Hospital, MRI Unit, Sutton, Surrey, UK
| | - M van den Bosch
- Image Sciences Institute/Imaging Division, University Medical Center Utrecht, The Netherlands
| | - L W Bartels
- Image Sciences Institute/Imaging Division, University Medical Center Utrecht, The Netherlands
| | - Y-S Kim
- Department of Radiology and Center for Imaging Science, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, South Korea; Department of Radiology, Mint Hospital, Seoul, South Korea
| | - M Deppe
- Philips MR Therapy, Äyritie 4, 01510 Vantaa, Finland
| | - N M deSouza
- The CRUK Cancer Imaging Centre, The Institute of Cancer Research and Royal Marsden Hospital, MRI Unit, Sutton, Surrey, UK
| |
Collapse
|
11
|
Reliability and validity of the Turkish version of the EORTC QLQ-C15-PAL for patients with advanced cancer. Palliat Support Care 2016; 14:628-634. [PMID: 27068607 DOI: 10.1017/s1478951516000195] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE Assessing quality of life, which is the main focus of palliative care, is highly important. The number of available, specific, simple, and valid assessment instruments for patients with advanced cancer in Turkey is limited. The aim of our study was to perform a psychometric evaluation of the Turkish version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 15-PAL (EORTC QLQ-C15-PAL). METHOD The study was conducted in İzmir with patients who had received treatment in the palliative care unit of a university hospital between November of 2011 and December of 2013. Sociodemographic and disease characteristics forms, the Karnofsky Performance Status (KPS) Scale, and the EORTC QLQ-C15-PAL Scale were employed in order to gather data. RESULTS A total of 150 patients completed the study: 55.3% of participants were female, 80.7% were married, and the average age was 52.76 ± 14.55. The value of Cronbach's α in the analyses ranged from 0.93 to 0.98. Most questionnaire areas had low to moderate correlations with the others. The moderate correlations were between fatigue and physical function (-0.41) and between insomnia and emotional function (-0.53). Conversely, weak correlations were found between nausea/vomiting and appetite loss (0.31) and between insomnia and pain (0.22). KPS scores decreased, patient physical and emotional function were diminished, global QoL declined, and patients' symptoms became more frank. SIGNIFICANCE OF RESULTS We concluded that the EORTC QLQ-C15-PAL is a valid and reliable tool to determine the quality of life of advanced cancer patients who are undergoing palliative treatment in Turkey.
Collapse
|
12
|
Costantini M, Rabitti E, Beccaro M, Fusco F, Peruselli C, La Ciura P, Valle A, Suriani C, Berardi MA, Valenti D, Mosso F, Morino P, Zaninetta G, Tubere G, Piazza M, Sofia M, Di Leo S, Higginson IJ. Validity, reliability and responsiveness to change of the Italian palliative care outcome scale: a multicenter study of advanced cancer patients. BMC Palliat Care 2016; 15:23. [PMID: 26920738 PMCID: PMC4768331 DOI: 10.1186/s12904-016-0095-6] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2015] [Accepted: 02/18/2016] [Indexed: 03/25/2024] Open
Abstract
BACKGROUND There is an increasing requirement to assess outcomes, but few measures have been tested for advanced medical illness. We aimed to test the validity, reliability and responsiveness of the Palliative care Outcome Scale (POS), and to analyse predictors of change after the transition to palliative care. METHODS Phase 1: multicentre, mixed method study comprising cognitive and qualitative interviews with patients and staff, cultural refinement and adaption. Phase 2: consecutive cancer patients on admission to 8 inpatient hospices and 7 home-based teams were asked to complete the POS, the EORTC QLQ-C15-PAL and the FACIT-Sp (T0), to assess internal consistency, convergent and divergent validity. After 6 days (T1) patients and staff completed the POS to assess responsiveness to change (T1-T0), and agreement between self-assessed POS and POS completed by the staff. Finally, we asked hospices an assessment 24-48 h after T1 to assess its reliability (test re-test analysis). RESULTS Phase I: 209 completed POS questionnaires and 29 cognitive interviews were assessed, revisions made and one item substituted. Phase II: 295 consecutive patients admitted to 15 PCTs were approached, 175 (59.3 %) were eligible, and 150 (85.7 %) consented. Consent was limited by the severity of illness in 40 % patients. We found good convergent validity, with strong and moderate correlations (r ranged 0.5-0.8) between similar items from the POS, the QLQ-C15-PAL and the FACIT-Sp. As hypothesised, the physical function subscale of QLQ-C15-PAL was not correlated with any POS item (r ranged -0.16-0.02). We found acceptable to good test re-test reliability in both versions for 6 items. We found significant clinical improvements during the first week of palliative care in 7/10 items assessed-pain, other symptoms, patient and family anxiety, information, feeling at peace and wasted time. CONCLUSIONS Both the patient self-assessed and professional POS versions are valid and with an acceptable internal consistency. POS detected significant clinical improvements during palliative care, at a time when patients are usually expected to deteriorate. These results suggest that there is room for substantial improvement in the management of patients with advanced disease, across all key domains-symptoms, psychological, information, social and spiritual.
Collapse
Affiliation(s)
- Massimo Costantini
- />Palliative Care Unit, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy
| | - Elisa Rabitti
- />Palliative Care Unit, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy
| | - Monica Beccaro
- />Academy of Sciences of Palliative Medicine, Bentivoglio, Bologna Italy
| | - Flavio Fusco
- />Palliative Care Unit, ASL3 Genovese, Genoa, Italy
| | | | | | | | | | - Maria Alejandra Berardi
- />Psycho-Oncology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | | | | | - Piero Morino
- />Convento delle Oblate Hospice, Azienda Sanitaria, Florence, Italy
| | | | | | - Massimo Piazza
- />S. Felice a Ema Hospice, Azienda Sanitaria, Florence, Italy
| | | | - Silvia Di Leo
- />Psycho-Oncology Unit, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy
| | - Irene J. Higginson
- />Department of Palliative Care, Policy and Rehabilitation, Cicely Saunders Institute, King’s College London, London, UK
| |
Collapse
|
13
|
Chiu L, Chiu N, Chow E, Cella D, Beaumont JL, Lam H, Popovic M, Bedard G, Poon M, Wong E, Zeng L, Bottomley A. Comparison of Three Shortened Questionnaires for Assessment of Quality of Life in Advanced Cancer. J Palliat Med 2014; 17:918-23. [DOI: 10.1089/jpm.2014.0012] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Leonard Chiu
- Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
| | - Nicholas Chiu
- Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
| | - Edward Chow
- Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
| | - David Cella
- Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | | | - Henry Lam
- Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
| | - Marko Popovic
- Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
| | - Gillian Bedard
- Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
| | - Michael Poon
- Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
| | - Erin Wong
- Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
| | - Liang Zeng
- Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
| | - Andrew Bottomley
- European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium
| |
Collapse
|
14
|
Lee YJ, Suh SY, Choi YS, Shim JY, Seo AR, Choi SE, Ahn HY, Yim E. EORTC QLQ-C15-PAL quality of life score as a prognostic indicator of survival in patients with far advanced cancer. Support Care Cancer 2014; 22:1941-8. [PMID: 24577883 DOI: 10.1007/s00520-014-2173-8] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2013] [Accepted: 02/17/2014] [Indexed: 02/07/2023]
Abstract
PURPOSE Quality of life (QoL) and performance status predict survival in advanced cancer patients; these relationships have not been explored in the hospice palliative care setting. The aim of this study was to examine the survival predictability of patient-reported QoL using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C15-PAL questionnaire in far advanced cancer inpatients at the very end of life. METHODS This is a retrospective cohort study. Patients reported QoL using the EORTC QLQ-C15-PAL. One hundred sixty-two inpatients in hospice palliative wards of six hospitals in South Korea were followed until death or the end of the study. Additional symptoms and performance status were assessed by the MD Anderson Symptom Inventory-Korean (MDASI-K), Palliative Performance Scale (PPS) and Eastern Cooperative Oncology Group (ECOG) performance status. Correlations between EORTC QLQ-C15-PAL, MDASI-K, PPS, and ECOG were assessed. Survival analyses were performed using Cox proportional hazard models. RESULTS Patients' median survival was less than 1 month. Physician-reported PPS significantly predicted survival (hazard ratio [HR] 0.493; p<0.001). From the EORTC QLQ-C15-PAL, patient-reported physical functioning predicted survival (HR=0.65; p<0.001). Other six domains of EORTC QLQ-C15-PAL were significantly related to survival after adjustment. Those domains were global health status, emotional functioning, fatigue, nausea/vomiting, appetite loss, and constipation. CONCLUSIONS EORTC QLQ-C15-PAL can be an independent prognostic factor in inpatients with far advanced cancer. Patient-reported physical functioning showed survival predictability as good as physician-reported performance status. It is notable that the QLQ instrument is useful even for patients in their final month of life. Cancer anorexia-cachexia syndrome-related symptoms may be independent prognostic symptoms. Prospective study is warranted.
Collapse
Affiliation(s)
- Yong Joo Lee
- College of Medicine, The Catholic University of Korea, Seoul, South Korea
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Arraras JI, de la Vega FA, Asin G, Rico M, Zarandona U, Eito C, Cambra K, Barrondo M, Errasti M, Verdún J, Rivadeneira J, Dominguez MA. The EORTC QLQ-C15-PAL questionnaire: validation study for Spanish bone metastases patients. Qual Life Res 2013; 23:849-55. [PMID: 24002479 DOI: 10.1007/s11136-013-0511-9] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/21/2013] [Indexed: 11/12/2022]
Abstract
PURPOSE Quality of life (QL) is a key outcome for advanced disease cancer patients. The European Organization for Research and Treatment of Cancer (EORTC) has developed the QLQ-C15-PAL questionnaire, a short version of the QLQ-C30 for palliative care. The aim of the present study is to validate the QLQ-C15-PAL for use with Spanish patients with bone metastasis. METHODS For this study, we used a consecutive sample of stage IV cancer patients with bone metastases who started radiotherapy with palliative intention. Two assessments were proposed for each patient: one on the first day of treatment and one a month after the end of the radiotherapy sessions. Psychometric evaluation of the structure, reliability, and validity was undertaken. RESULTS One hundred and sixteen patients completed the first questionnaire and seventy five completed the second. Multitrait scaling analysis showed that all items met the standards for convergent validity, and all except the fatigue scale met the standards for divergent validity. Cronbach's coefficient met the 0.7 alpha criterion on all scales except pain (second assessment). Most QLQ-C15-PAL areas had low-to-moderate correlations with the other areas. Significant differences appeared in the comparisons between groups with regard to: patients who died before the second assessment (six areas); patients receiving chemotherapy before starting radiotherapy in the two assessments (three and four areas, respectively); the performance status in the two assessments (nine and eight areas); and the number of RT sessions received (four). Quality of life was better in the second assessment in nine areas. CONCLUSION The QLQ-C15-PAL is a reliable and valid instrument when applied to a sample of Spanish patients. These results are in line with those of other validation studies.
Collapse
Affiliation(s)
- Juan Ignacio Arraras
- Radiotherapeutic Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain,
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Current World Literature. Curr Opin Support Palliat Care 2012; 6:543-52. [DOI: 10.1097/spc.0b013e32835ad036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|